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Objectives: To investigate antimicrobial susceptibility in Staphylococcus pseudintermedius and the occurrence of
methicillin-resistant S. pseudintermedius (MRSP), to explore the molecular structure of the MRSP population and
to analyse risk factors for MRSP.
Methods: Susceptibility data for clinical S. pseudintermedius isolates in 2011–15 were analysed using WHONET.
All MRSP isolates in 2010–14 (n"362) were typed using PFGE. Representative isolates (n"87) of clusters were
analysed using MLST and staphylococcal cassette chromosomemec (SCCmec) typing. Risk factors were analysed
using logistic regression.
Results:Of the clinical S. pseudintermedius (n"1958; 98% from dogs), 14% were MRSP. Resistance to other anti-
microbials varied between 12% and 39%. No trends were observed over time. Among clinical specimens (from
infection sites) and screening specimens (from potential carriers), respectively, 2.5% (267/10 813) and
9% (211/2434) revealed MRSP. MLST revealed 42 different STs, including 19 new ones. Clonal complexes 71, 45
and 258 were the most common, but the MRSP population diversified over the years. A clinical S. pseudinterme-
dius isolate was more likely to be MRSP if the patient was on antimicrobials at the time of sampling or was male.
The presence of MRSP in screening specimens was more likely if the patient was on multiple antimicrobials at the
time of sampling. Specimens from private clinics (versus the Veterinary Teaching Hospital of the University of
Helsinki) had a higher likelihood of MRSP in both analyses.
Conclusions: Resistance to antimicrobials among S. pseudintermedius in Finland is high, emphasizing the import-
ance of infection control measures and susceptibility testing prior to therapy. The diverse MRSP population indi-
cates non-clonal spread.
Introduction
Staphylococcus pseudintermedius is a part of the normal micro-
biota of dogs and cats.1,2 This opportunistic bacterium can cause a
wide range of infections, ranging from pyoderma and surgical
wound infections to deep infections such as osteomyelitis.3–6 Over
the past decade, methicillin-resistant S. pseudintermedius (MRSP)
has become a worldwide problem in small animal veterinary medi-
cine.7,8 Ever fewer effective antimicrobials are available for treat-
ment, as MRSP isolates are commonly MDR.8–10
The epidemiology and molecular characteristics of MRSP in
neighbouring countries, such as Sweden and Norway, have already
been explored.11–13 There is evidence that the clonal structure of
MRSP is changing in some countries.13,14 In Finland, a large veterin-
ary hospital outbreak in 2010–11 was caused by the predominant
European MRSP clone, ST71.15 The study also identified ST45 as
causing a smaller cluster. These two main clones were additionally
identified among Finnish guide dogs, but the presence of other un-
related STs indicated diversity in the MRSP population.16 However,
no study has extensively explored the epidemiology of MRSP in
Finland. The goal of this study was to investigate the epidemiology
of S. pseudintermedius in Finland during 2010–15 by (i) reporting
the antimicrobial susceptibility time trends of clinical isolates in
2011–15, (ii) exploring the molecular structure of the MRSP popula-
tion in 2010–14, (iii) describing yearly MRSP proportions in clinical
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specimens and screening specimens from potential carriers and
(iv) determining risk factors for MRSP among screening specimens
and for a clinical S. pseudintermedius being MRSP.
Methods
Study setting
The investigation was carried out at the Clinical Microbiology Laboratory of
the Faculty of Veterinary Medicine, University of Helsinki. In 2011–15, the la-
boratory processed 19 249 microbiological specimens.
Data collection
For analysis of antimicrobial susceptibility, results for all isolates identified
as S. pseudintermedius15,17,18 between June 2011 and the end of 2015
were compiled from the laboratory information system (LIS) (Provet Net,
Finnish Net Solutions, Finland). In addition, patient information data (spe-
cies, sex, specimen type, presence of antimicrobial therapy at the time of
sampling, and submitting clinic) were collected. Antimicrobials tested in
the basic panel included clindamycin, erythromycin, fusidic acid, oxacillin,
trimethoprim/sulfamethoxazole and tetracycline. Comparable data for the
extended panel (amikacin, chloramphenicol, doxycycline, enrofloxacin and
gentamicin) were only available for 2015. Susceptibility testing was per-
formed by disc diffusion according to CLSI standards.19,20
Molecular methods
Suspected MRSP isolates, based on resistance to oxacillin,20 were confirmed
to carry the mecA gene by PCR.16 All confirmed isolates were stored at
#80C until further studied. To detect clonal clusters, all MRSP isolates
stored in 2010–14 were digested by SmaI macrorestriction (New England
BioLabs, USA) and separated by PFGE21 with modifications.15 Isolates that
were non-typeable by SmaI were digested using AscI (New England
BioLabs, USA). PFGE clusters were illustrated with GelCompar II (v. 6.5;
Applied Maths NV, Belgium) by UPGMA-based analysis using the Dice simi-
larity coefficient with an 80% similarity cut-off; optimization and position
tolerance were set at 1.2% and 1.3%, respectively. At least one isolate from
each PFGE cluster was selected for further characterization by MLST and
staphylococcal cassette chromosome mec (SCCmec) typing,22,23 with
modifications.16 For some isolates, the MLST sequencing result for the
tuf gene was poor with published primers.22 Therefore, the primers were
modified as follows: tuf 19F, 50-GTCCAATGCCACAAACTCG-30; and tuf 19R,
50-CCAGCTTCAGCGTAGTCTA-30. MLST results for isolates were extrapolated
to all members of the PFGE cluster. Isolates for which data had previously
been published were included in the study.15,16
Data analysis
Susceptibility data for clinical S. pseudintermedius isolates (screening speci-
mens excluded) were analysed using WHONET (v. 5.6, WHO). Non-
susceptibility percentages, including resistant and intermediate isolates,
with 95% CIs, were calculated and presented separately for MRSP,
methicillin-susceptible S. pseudintermedius (MSSP) and all S. pseudinterme-
dius isolates. CLSI breakpoints were used,19,20 except for fusidic acid, for
which a non-susceptibility breakpoint of23 mm was used.24 Yearly trends
for non-susceptibility percentages were plotted and trends were investi-
gated using a Cochran–Armitage trend test for each antimicrobial. The stat-
istical difference in non-susceptibilities between MRSP and MSSP was
investigated using Pearson’s v2 test based on the WHONET output. P values
,0.05 were considered statistically significant. Analyses were performed
with the SASV
R
System for Windows (v. 9.3, USA). To calculate the number of
MDR isolates (resistance to at least three antimicrobial classes), macrolide
and lincosamide resistance was pooled due to common MLSB resistance
(macrolide, lincosamide and streptogramin B).25
The proportions of MRSP in clinical and screening specimens were calcu-
lated for dogs and cats in order to derive crude prevalence estimates for
MRSP in dogs and cats seeking veterinary care, from which microbiological
specimens are obtained, and in high-risk populations, respectively. Patients
in the latter populations have previously identified risk factors for MRSP,
such as frequent antimicrobial exposure, chronic or intermittent infection,
such as pyoderma, surgical site infection or previous exposure to MRSP
(either in hospital or family).15 Screening is targeted at these patients.
To compare the genetic relatedness of STs, the allele sequences for each
ST were added back-to-back (ack, cpn60, fdh, pta, purA, sar, tuf). The result-
ing sequences were aligned and a phylogenetic tree was inferred by the
Bayesian Markov Chain Monte Carlo (MCMC) method implemented in BEAST
(v. 1.7.2).26 Each run was continued until the effective sample size (ESS) was
.200. Posterior probabilities were calculated with a 10% burn-in and values
.0.7 were considered significant. Results were visualized in FigTree (v. 1.40).
Additionally, goeBURST (v 1.2.1) software was used for population structure
analysis of STs.27 Analysis was conducted at double- and triple-locus variant
levels. Single- and double-locus variants of previously described clonal com-
plexes (CCs) were assigned to that CC.14 The number of isolates per ST or CC
per year was calculated based on the specimen collection date.
For analysis of predictors for MRSP, data were analysed separately for
clinical S. pseudintermedius isolates and screening specimens by logistic re-
gression with MRSP as the outcome variable. As data from the MRSP out-
break at the Veterinary Teaching Hospital of the University of Helsinki (VTH)
in 2010–11 were likely to skew the results, data for this period were omit-
ted.15 Due to the low number of cats in the data (n"18 for clinical speci-
mens and zero positive out of 145 for screening specimens), these, as well
as specimens from unknown species (n"11), were omitted from the ana-
lyses. ORs with 95% CI and P values were calculated for each variable.
Variables with a P value 0.2 in the univariable analysis were included in
the multivariable analysis. Multivariable logistic regression was performed
using a backward step (Wald) method. P values ,0.05 were considered
statistically significant in the final model. Analyses were performed using
SPSS v. 24 (IBM Inc.).
Results
Clinical S. pseudintermedius isolates
Results were available from a total of 1958 clinical
S. pseudintermedius isolates. Of these, 1471 (75%) were from spe-
cimens from private clinics, while 487 were from the VTH. The iso-
lates were mainly from dogs, comprising 1928 isolates (98%),
while 18 isolates (0.9%) originated from cats. One S. pseudinter-
medius isolate was from a guinea pig. In 11 cases (0.6%), the spe-
cies had not been recorded. The majority of specimens (n"1507;
77%) were obtained from superficial sites, such as ears and skin,
while 284 (15%) were from deep lesions (e.g. deep wounds,
abscesses or synovial fluid). The bacterium was also recovered
from urine (n"98; 5%), respiratory specimens (n"6; 0.3%)
and blood cultures (n"2; 0.1%). The rest (n"61; 3%) were from
cultured agar plates that had been sent to the laboratory for fur-
ther testing.
Antimicrobial susceptibility and occurrence of MRSP
Out of the 1958 clinical S. pseudintermedius isolates, the overall
proportion of oxacillin (methicillin) resistance was 14% (n"266).
Non-susceptibility data for all tested antimicrobials for MRSP, MSSP
and overall are presented in Table 1. The proportion of non-
susceptible isolates per year varied only slightly for each antimicro-
bial and no statistically significant trends were detected (Figure 1).
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Figure 1. Non-susceptibility percentages by year with 95% CIs for clinical S. pseudintermedius isolates in Finland from mid-2011 to the end of 2015.
Cochran–Armitage trend test P values were 0.14 for CLI (clindamycin), 0.14 for ERY (erythromycin), 0.86 for FUS (fusidic acid), 0.12 for OXA (oxacillin),
0.22 for SXT (trimethoprim/sulfamethoxazole) and 0.40 for TET (tetracycline).
Table 1. Antimicrobial non-susceptibility among clinical S. pseudintermedius isolates from mid-2011 to the end of 2015 in Finland
Antimicrobial
MRSP MSSP All
% non-
susceptible 95% CI
number of
isolates
% non-
susceptible 95% CI
number
of isolates
% non-
susceptible 95% CI
number of
isolates
Basic panel
clindamycina 85.7 80.8–89.6 265 22.2 20.2–24.3 1678 30.8 28.8–32.9 1947
erythromycina 85.7 80.8–89.6 266 21.8 19.9–23.9 1678 30.5 28.5–32.6 1949
fusidic acid 24.5 19.5–30.2 265 24.3 22.3–26.4 1677 24.4 22.5–26.4 1946
oxacillina 100 98.2–100 266 0 0.0–0.3 1682 13.7 12.2–15.3 1948
tetracyclinea 74 68.2–79.1 265 33.3 31.1–35.6 1675 38.8 36.6–41.0 1944
trimethoprim/sulfamethoxazolea 47.7 41.6–53.9 266 6.1 5.0–7.4 1680 11.8 10.4–13.3 1951
MRSP MSSP All (2015)b
% non-
susceptible 95% CI
number of
isolates
% non-
susceptible 95% CI
number
of isolates
% non-
susceptible 95% CI
number of
isolates
Extended panel
amikacin 0 0.0–2.1 219 0 0.0–0.9 547 0 0.0–1.2 393
chloramphenicola 46.9 29.5–65.0 32 15 10.6–20.8 207 18.4 13.7–24.2 228
doxycyclinea 28.8 18.6–41.4 66 4.7 2.8–7.7 342 6.1 4.0–9.1 392
enrofloxacina 50.4 44.0–56.8 248 2.6 1.7–4.0 793 7.3 5.0–10.4 395
gentamicina 44.8 38.5–51.2 248 2.5 1.6–3.9 795 6.6 4.4–9.6 395
aStatistically significant (P,0.001) difference between MRSP and MSSP.
bConsistent data only available for 2015, as the extended panel was only investigated for MRSP or otherwise MDR isolates prior to this.
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A complete basic panel antibiogram was recorded for 1932 (99%)
isolates. Of these, 17% (321 isolates) were MDR. The most common
MDR profile (78/321; 24%) was lincosamides/macrolides–oxacillin–
trimethoprim/sulfamethoxazole–tetracycline. Twelve isolates were
non-susceptible to all six antimicrobials investigated, while 36%
(700/1932) were fully susceptible. The proportion of MRSP among
clinical and screening specimens by year is presented in Table 2.
Molecular characteristics of MRSP
Out of the 362 MRSP isolates (197 from clinical specimens,
165 from screening specimens), 279 were typeable using SmaI
macrorestriction. These clustered into 19 (A–S) different clusters
with four or more isolates (Figure S1, available as Supplementary
data at JAC Online). Eighty-three isolates could only be typed by
AscI macrorestriction and formed two clusters (T and U) and one
singleton in PFGE analysis (Figure S2). In total, 87 isolates from
71 different PFGE clusters or singletons (SmaI or AscI) were investi-
gated by MLST and SCCmec.
Forty-two different STs were identified, including 19 new STs
(STs 621 and 625 to 642).28 All SmaI non-typeable isolates be-
longed to CC45. The proportion of isolates from each CC or ST
changed from year to year, indicating increasing diversity in the
MRSP population (Figure 2). All identified STs and their clonal and
genetic relatedness are presented in Figure 3(a and b). Six STs
grouped together with previously described CCs (CC45 and CC258)
(Figure 3a).14 STs in the CC258 group were scattered in the se-
quence comparison tree, while STs in the CC45 group were more
alike (Figure 3b).
Four different SCCmec types, covering 60 out of the 87 (69%)
investigated isolates, were identified. Twenty-seven isolates (31%)
were non-typeable, either due to a lack of a PCR product or be-
cause the result did not match SCCmec types I–VI (Figure S3). The
number of isolates found to carry each SCCmec, as well as the STs
in which these were found, are presented in Table 3.
Table 2. Proportion of MRSP per year among clinical and screening specimens from dogs and cats in Finland in 2011–15
Year
Clinical specimens Screening specimens
dogs cats dogs cats
MRSP %
number of
specimens MRSP %
number of
specimens MRSP %
number of
specimens MRSP %
number of
specimens
2011 June!a 3.6 933 2.3 130 9.2 347 11.5 52
2012 3.3 2076 0.3 358 8.4 452 0.0 59
2013 2.6 2104 0.0 368 6.2 436 0.0 28
2014 2.6 1963 0.3 382 10.2 551 0.0 24
2015 2.5 2098 0.2 401 11.5 451 0.0 34
Total 2.8 9174 0.4 1639 9.2 2237 3.0 197
aThe MRSP outbreak at the VTH was still ongoing in 2011.
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Figure 2. Proportion of CCs or STs of MRSP by year in 2010–14. The data are based on extrapolation of MLST analysis results to the corresponding
PFGE cluster. Numbers at the top of the columns indicate the number of isolates. Other, miscellaneous STs.
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Predictors of MRSP
According to the results of multivariable logistic regression ana-
lysis, a clinical S. pseudintermedius isolate was more likely to be
MRSP if the specimen was from a private clinic (14% of isolates ver-
sus 9% of isolates from the VTH), the patient was male or the
patient was on any antimicrobials. Among patients who had
received antimicrobials, those receiving b-lactams had higher
odds of MRSP (Table 4). For screening specimens, the detection of
MRSP was more likely if the patient was being treated with multiple
systemic antimicrobials (most commonly a combination of
(a)
(b)
Figure 3. Genetic relationship of MRSP in Finland (2010–14). (a) goeBURST analysis conducted at the double-locus variant level, with triple-locus variants
(connected with grey dashed lines) added to show further relatedness. Line numbers and shading indicate the number of differing loci between STs.
Grey areas highlight CCs. Grey boxes with black text, group founder; black boxes with white text, sub-group founder; white boxes with black text, com-
mon node; grey boxes with white text, triple-locus variant. (b) A phylogenetic tree based on the alignment of all MLST genes of each ST. Only posterior
probabilities .0.7 are shown. Grey shades indicate CC groups as assigned by goeBURST analysis. *CC founder; †single-locus variant; ‡double-locus
variant.
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ampicillin and enrofloxacin) or if the specimen was from a private
clinic (Table 5).
Discussion
The proportion of MRSP among clinical S. pseudintermedius isolates
was fairly high, being nearly 14%. The high percentage (17%) in
2011 was influenced by the MRSP outbreak at the VTH.15
Interestingly, the proportions of MRSP among isolates from private
clinics and the VTH were significantly different. This difference may
be due to dissimilar patient populations. While the VTH is a national
referral veterinary hospital, it also treats first-opinion patients.
Numerous clinical specimens originated from private clinics
that are treating many dermatological patients, a group at risk of
MRSP due to frequent antimicrobial therapy and veterinary vis-
its.15,16,29–31 A threshold to obtain bacteriological specimens early
in the infection process is probably higher among private clinic vet-
erinarians. The VTH has had a strict policy of obtaining specimens
in all cases of suspected bacterial infection since the MRSP out-
break in 2010–11.15 It is also likely that screening criteria for risk
patients are wider at the VTH compared with private clinics, which,
in our experience, mainly screen dermatological patients. As the
specimens from private clinics may predominantly originate from
chronic cases, a higher rate of resistant bacteria would be ex-
pected. A comparable difference in patient populations was the
likely explanation for unequal methicillin resistance rates between
two laboratories in the UK.32 At the microbiology laboratory of the
Royal Veterinary College (RVC), 14% of Staphylococcus intermedius
group isolates in 2006–12 were oxacillin resistant, while oxacillin
resistance in another laboratory was only 1%. This difference
was attributed to the high resistance among referral animals of
the RVC.32
Non-susceptibility to antimicrobials was significantly higher
among MRSP isolates than MSSP isolates, except for fusidic acid, for
which non-susceptibility was around 24% in both. Similar findings
apply to MRSA and MSSA.33 Resistance to fusidic acid among
S. pseudintermedius has varied between studies. In Sweden, 20% of
isolates were resistant to fusidic acid in 2015 (MIC1 mg/L),13 which
is similar to our results. In Norway, nearly half of S. pseudintermedius
isolates investigated were fusidic acid resistant (MIC 1 mg/L).34
Table 3. Number of MRSP isolates with each identified SCCmec and the STs associated with them
SCCmec Number of isolates ST(s)
II 1 498
II–III 19 71
IV 37 258, 342, 413, 415, 475, 561, 592, 621, 625, 626, 630, 631, 632, 633, 634, 635, 638, 639, 640, 641
V 3 183, 404, 642
Non-typeable 27 21, 41, 45, 84, 121, 150, 152, 263, 298, 305, 402, 403, 561, 628, 636, 637
Table 4. Risk factors associated with the discovery of MRSP among canine clinical S. pseudintermedius isolates taken during 2012–15
MRSP (n"227) MSSP (n"1501) Univariable logistic regression Multivariable logistic regression
na %a na %a
unadjusted OR
(95% CI) univariate P
adjusted OR
(95% CI) Wald P
Private clinic versus university
teaching hospital
192 84.6 1140 75.9 1.74 (1.19–2.54) 0.004 1.88 (1.25–2.81) 0.003
Gender: male versus female 150 67.6 761 52.3 1.90 (1.41–2.56) ,0.001 1.83 (1.34–2.51) ,0.001
Deep lesion specimen 31 13.7 234 15.6 0.86 (0.57–1.28) 0.452
Superficial lesion specimen 173 76.2 1147 76.4 0.99 (0.71–1.37) 0.946
Urine specimen 8 3.5 81 5.4 0.64 (0.31–1.34) 0.238
Other specimens 15 6.6 39 2.6 2.65 (1.43–4.90) 0.002 1.65 (0.77–3.51) 0.196b
Antimicrobial treatment during
sampling
84 40.2 264 19.1 2.84 (2.09–3.87) ,0.001 2.67 (2.09–3.93) ,0.001
Antimicrobial groupsc
systemic b–lactams 60 71.4 150 57.3 1.87 (1.10–3.18) 0.022 1.87 (1.10–3.18) 0.022
multiple systemic antimicrobials 1 1.2 6 2.3 0.51 (0.06–4.33) 0.541
other systemic antimicrobials 15 17.9 63 23.9 0.25 (0.37–1.30) 0.252
topical antimicrobials 8 9.5 40 15.3 0.58 (0.26–1.30) 0.189 0.90 (0.35–2.29) 0.825b
P values in bold indicate variables included in multivariate analysis (P0.2).
an refers to the number of dogs with the factor in question, while % refers to the proportion out of the total number of dogs from which data were
available, for example, antimicrobial treatment data were available from 209 dogs among MRSP cases (84/0.402).
bVariables eliminated from the final models.
cAntimicrobial group variables were analysed separately for patients that had received antimicrobials.
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On the other hand, an Italian study did not find fusidic acid resist-
ance in S. intermedius.35
A recent report from Sweden details resistance among
S. pseudintermedius collected from skin lesions.13 Although our
data also include isolates from other sources, the difference in oxa-
cillin resistance, in particular, is exceptional, being 2% in the
Swedish data and 14% in our data for 2015. Similar differences
can be seen among other tested antimicrobials, which is concern-
ing. These differences may reflect contrasts in the use of
antimicrobials and infection control policies in these countries.
Due to the high resistance for commonly used antimicrobials in
S. pseudintermedius in Finland, clinicians are strongly encouraged
to take specimens for bacterial cultures early in the disease process
to ensure the efficacy of the intended treatment. This is also stated
in the newly published national guidelines on the use of antimicro-
bials in animals.36 In addition, since S. pseudintermedius is a com-
mon finding in infections associated with dermatological diseases,
it is vital that any underlying disease process is properly controlled
to avoid the unnecessary use of antimicrobials. More research is
required to determine the value of antimicrobial therapy in pa-
tients when underlying conditions have been controlled.
Furthermore, the high resistance among S. pseudintermedius
could warrant making MRSP a notifiable animal disease in Finland,
as it is in Sweden.13
Regarding other risk factors, clinical and screening specimens
were investigated separately, as they were thought to represent
different populations (see Methods section). We are unaware of
any other country where routine MRSP screening, similar to screen-
ing for MRSA, for instance, in the Netherlands,37 would be part of
an MRSP control scheme. The specimens are taken from patients
that are deemed to have a higher risk of MRSP.15 Currently, many
of the private clinics that submit specimens to our laboratory
screen particularly dermatological patients. While antimicrobial
therapy has been indicated as a risk factor for MRSP in multiple
studies,15,16,30,38 no study, to our knowledge, has yet reported
gender as potentially being one. S. pseudintermedius from clinical
specimens of males were more likely to be MRSP (16.4% versus
9.4%). The reason for this is unclear. Studies have not found sex to
be a predisposing factor for atopic dermatitis or food allergy.39–41
It is possible that there is some unknown variable that could ex-
plain the result. It may also be only due to chance, as gender was
not observed to be a risk factor for MRSP in screening specimens.
Clinical specimens from dogs revealed more S. pseudintermedius
and MRSP than those from cats. Furthermore, not a single MRSP
was isolated from feline screening specimens after 2011
(n"145). These results are unsurprising, as both S. pseudinterme-
dius and MRSP colonization are less common in cats.42,43
Screening of cats for MRSP carriage, even if they have risk factors, is
thus deemed unnecessary.
MRSP was detected in 2.5% of all clinical specimens (regardless
of whether they revealed S. pseudintermedius), a proportion simi-
lar to the MRSP prevalence in the Finnish guide dog population
(3%).16 While this figure of 2.5% is not a true prevalence, it may be
used as a crude approximation of the prevalence in an average
small-animal population from which bacterial cultures have been
taken, in order to design future prevalence studies.
The identification of 23 previously identified and 19 new STs is a
testament to the diverse nature of the MRSP population in Finland.
A changing trend was evident, as the population diversified during
the time frame investigated. Note, however, that in 2010–11
many isolates originated from the VTH outbreak.15 Before the out-
break, MRSP was a very uncommon finding in the VTH, although
previously published surveillance data indicate that MRSP arrived
in force in Finland in 2009, when a sharp increase in MRSP propor-
tion was observed.44 A Swedish study (isolates from 2008 to mid-
2010) showed a fairly homogeneous MRSP population, with 96%
(216/226) of the isolates representing the predominant European
lineage, ST71.11 This clone was also the most common ST in
Finland in 2010–11, but has diminished since (Figure 2). Similarly to
our data, a change in the MRSP population has also been observed
in Sweden after 2010.13 There, 20 out of 58 MRSP isolates (34%)
were ST258 in 2015.13 CC258 was the third most common CC in
Table 5. Risk factors associated with the discovery of MRSP among canine screening specimens taken during 2012–15
MRSP positive
(n"173)
MRSP negative
(n"1717)
Univariable logistic
regression
Multivariable logistic
regression
na %a na %a
unadjusted OR
(95% CI) univariate P
adjusted OR
(95% CI) Wald P
Private clinic versus university
teaching hospital
67 38.7 521 30.3 1.45 (1.05–2.00) 0.024 1.54 (1.09–2.18) 0.015
Gender: male versus female 92 54.4 849 50.2 1.19 (0.86–1.63) 0.295
Antimicrobial treatment during
samplingb
45 29.4 446 28.5 1.04 (0.73–1.50) 0.815
Systemic b-lactams 20 13.1 219 14.0 0.92 (0.57–1.51) 0.751
Multiple systemic antimicrobials 10 6.5 56 3.6 1.88 (0.94–3.77) 0.074 2.14 (1.06–4.32) 0.034
Other systemic antimicrobials 7 4.0 108 6.3 0.63 (0.29–1.37) 0.243
Topical antimicrobials 6 3.9 45 2.9 1.38 (0.58–3.28) 0.470
P values in bold indicate variables included in multivariate analysis (P0.2).
an refers to the number of dogs with the factor in question, while % refers to the proportion out of the total number of dogs from which data were
available, for example, antimicrobial treatment data were available from 153 dogs among MRSP cases (45/0.294).
bAntimicrobial treatment in general was not significant in the univariable analysis and antimicrobial groups were therefore included in the model.
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our study and was the largest clone in Norway in a recent study.12
Additionally, CC258 has recently been reported as a major CC in
both the Netherlands14 and Denmark.45 These studies also re-
ported a marked diversity in the MRSP population in recent
years.14,45 It appears that ST71 has lost its sustainability and
CC258 is only filling the gap as a more successful lineage. ST71 car-
ries SCCmec II–III, which has only been found in related STs and
ST354.45,46 The immobility of this element may be an underlying
reason for the demise of the clone. In contrast, our data indicate
that SCCmec IV, in particular, is readily transferred between differ-
ent clones, or is received from other staphylococci, as it was identi-
fied in 20 different STs. The acquisition of SCCmec elements by
MSSP from MRSP, CoNS or MRSA may explain the plethora of STs in
MRSP. Our findings indicate that the epidemiology of MRSP is
changing; clonal spread is becoming less significant and the
spread of SCCmec elements is more common. This could make it
more difficult to control the spread of MRSP.
Contrary to CC71, CC45 has maintained a steady proportion,
with an annual share of the MRSP isolates of 20% in 2011–14.
Representatives of this CC have been detected at least in
Sweden,47 the Netherlands14 and in Israel and Thailand,48,49 but
have been rather rare in reports from Europe.14,47 Representatives
of ST45 are typically non-typeable by SmaI PFGE,48 as was the
case in our study. Interestingly, 80% (66/83) of CC45 isolates
showed the same basic antibiogram, only being susceptible to tri-
methoprim/sulfamethoxazole and fusidic acid (Figure S2). The dis-
tribution of STs among clinical isolates and screening isolates was
similar, with ST71 being the most common and ST45 being the se-
cond most common ST in both groups (data not shown).
The sequence alignment and eBURST analyses grouped the
identified STs quite differently. For example, STs 258 and 413,
single-locus variants, were placed in different groups in the max-
imum likelihood tree (six nucleotide differences in one locus), while
ST638, a double-locus variant of ST258, was deemed nearly identi-
cal to ST258 (four nucleotide differences in two loci) in the max-
imum likelihood tree (Figure 3a and b). Performing eBURST
analysis of MLST data has become common when analysing the
clonality of MRSP. However, it does seem to be a crude way of as-
signing genetic relatedness. A single locus, e.g. cpn60 alleles 1 and
10, may have 26 single-nucleotide differences. All other alleles
being identical, two isolates would be considered single-locus vari-
ants and be assigned the same CC. On the other hand, two isolates
that are triple-locus variants, but only by one nucleotide in each
locus (e.g. ack 1 and 2, fdh 1 and 5, and sar 1 and 7), would not be
assigned to the same CC, even though the total number of nucleo-
tide differences is much smaller (3–26). It could be beneficial to de-
termine genetic relatedness based on the actual sequences, as
was done by Kjellman et al.,12 rather than by comparing combin-
ations of allele numbers. It is, however, likely that WGS will replace
eBURST analysis once its costs decrease.
There are some limitations in this study. The specimens
mainly originated from southern Finland and may thus not re-
flect the resistance situation in the entire country. On the other
hand, the proportion of private clinic specimens rose from 16%
in 2011 to 47% in 2015, with nearly 200 submitting clinics,
which increased the geographical coverage. In addition, infor-
mation on risk factors, such as antimicrobial therapy, is prone to
reporting bias, as this information is more likely to be reported if
the animal is receiving treatment. This is unlikely to have im-
pacted our results, as the minimum data coverage for risk fac-
tors was 88%. In addition, susceptibility data may contain more
than one isolate from the same animal, which may have caused
bias in the data. The bias caused by this is, however, likely to be
minimal due to the large number of isolates and because such
isolates would probably be distributed evenly among suscep-
tible and resistant populations, and over the years.
Furthermore, PFGE was used as a screening method to find can-
didates for MSLT and SCCmec typing without having to type all
MRSP isolates, which was not feasible. It is therefore possible
that there are other, as yet unidentified STs among the isolates.
However, apart from one instance where multiple isolates had
been typed from a PFGE cluster, all belonged to the same CC.
Conclusions
To conclude, the high resistance to methicillin and other antimicro-
bials among S. pseudintermedius is of concern. Currently, MRSP in
Finland may be spreading via gene transfer rather than clonally,
which makes it more difficult to predict resistance patterns in
S. pseudintermedius and prevent MRSP. Additionally, routine
screening of cats for MRSP is not necessary due to the low occur-
rence, even among risk patients. We emphasize the need to obtain
a bacteriological specimen whenever antimicrobial therapy is indi-
cated. The importance of infection control in veterinary premises
should also be stressed as a means of preventing the spread of re-
sistance. The use of non-antimicrobial therapy should be con-
sidered whenever feasible.
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